

CORRECTION

Open Access



Correction: Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies

Ying Du^{1†}, Chao Zhao^{1†}, Juntong Liu^{1†}, Chuan Li^{1†}, Qi Yan¹, Lin Li¹, Yunfeng Hao¹, Dan Yao¹, Huaxing Si¹, Yingjun Zhao^{2*} and Wei Zhang^{1*}

Correction: *Journal of Neuroinflammation* (2022) 19:259
<https://doi.org/10.1186/s12974-022-02622-8>

Following publication of the original article [1], the authors identified an error in Table 1. The “*n*” numbers in the head row of Table 1 are incorrect and inconsistent.

The correct version of Table 1 is given in this correction (Table 1).

In “Results” section under the heading “clinical outcomes”. The X in sentence “Especially, during the study.....” should be updated with 11 and 1.

It should read as,

Especially, during the study, 12 patients in total 59 patients had 12 relapses (11 with NMDAR-AE, 1 with LGI1-AE).

The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12974-022-02622-8>.

[†]Ying Du, Chao Zhao, Juntong Liu and Chuan Li contributed equally to this work

*Correspondence: yjzhao@xmu.edu.cn; tdzw@fmmu.edu.cn

¹ Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an City 710038, Shaanxi Province, China

² Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen 361005, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Characterization of the patient cohort

	TOTAL				NMDAR-AE				LGI1-AE				CASPR2-AE			
	RTX (n = 18)	Ctrl (n = 41)	p value	RTX (n = 14)	Ctrl (n = 27)	p value	RTX (n = 3)	Ctrl (n = 9)	p value	RTX (n = 1)	Ctrl (n = 5)	p value	RTX (n = 1)	Ctrl (n = 5)	p value	
Gender, female/male	8/10	18/23	0.595	7/7	11/16	0.406	1/2	5/4	0.100	0/1	2/3	-				
Age at onset, years; mean (95% CI)	41.88 (33–50)	37.61 (32–42)	0.356	35.28 (27–42)	34.22 (28–40)	0.823	63.33 (48–78)	52.88 (43–62)	0.190	70 (/)	28.40 (19–37)	-				
From onset to diagnosis, days; median (IQR)	20 (78)	24 (52)	0.863	14.5 (23.75)	16 (51)	0.185	35 (/)	60 (63)	0.864	190 (/)	31 (41)	-				
Follow-up duration, days; mean (95% CI)	1058 (768–1349)	1362 (1136–1587)	0.120	1084 (802–1376)	1488 (1215–1556)	0.059	1086 (/)	1640 (1278)	0.926	244 (/)	561 (640)	-				
Symptoms; n (%)																
Seizures	66.7%	61.0%	0.455	71.4%	66.7%	0.100	66.7%	55.6%	0.100	0.00%	40%	-				
Cognitive impairment	94.4%	85.4%	0.422	92.9%	85.2%	0.645	100%	100%	-	100%	60%	-				
Psychiatric symptoms	83.3%	87.8%	0.690	78.6%	88.9%	0.393	100%	88.9%	0.100	100%	80%	-				
Decreased consciousness	44.4%	29.3%	0.201	57.1%	33.3%	0.189	0.0%	11.1%	0.100	0.0%	40%	-				
Autonomic dysfunction	27.8%	22.0%	0.742	28.6%	25.9%	0.100	33.3%	0.0%	0.250	0.0%	40%	-				
Movement disorder	44.4%	26.8%	0.151	50%	22.2%	0.089	33.3%	33.3%	0.100	0.0%	40%	-				
Fever	44.4%	39.0%	0.457	57.1%	51.9%	0.504	0.0%	11.1%	0.100	0.0%	20%	-				
CSF/MRI/EEG profiles																
CSF cc; median, (IQR)	7 (67)	8 (23)	0.613	8.5 (90.5)	1.2 (26)	0.264	4 (/)	2 (4)	0.282	2 (/)	1 (62)	-				
CSF protein; mean, (95% CI)	404.45 (318–490)	353.82 (288–419)	0.370	372.05 (274–469)	405.57 (313–497)	0.637	470.28 (93–847)	247.21 (179–314)	0.009	660.7 (/)	266.32 (144–387)	-				
CSF pressure; mean, (95% CI)	174.72 (146–203)	161.46 (140–182)	0.463	182.85 (147–218)	170.18 (140–199)	0.587	145.00 (46–243)	131.66 (100–162)	0.632	150 (/)	168.00 (121–214)	-				
MRI abnormalities; n (%)	50.0%	56.1%	0.440	64.3%	51.9%	0.336	0.0%	77.8%	0.045	0.0%	40%	-				
EEG abnormalities; n (%)	61.1%	43.9%	0.175	71.4%	48.1%	0.137	33.3%	33.3%	0.100	0.0%	40%	-				

Table 1 (continued)

	TOTAL				NMDAR-AE		LGI1-AE		CASPR2-AE		p value
	RTX (n = 18)	Ctrl (n = 41)	p value	RTX (n = 14)	Ctrl (n = 27)	p value	RTX (n = 3)	Ctrl (n = 9)	p value	RTX (n = 1)	
CSF/Serum Ab profiles											
CSF Ab positive	94.4%	80.5%	0.252	100%	88.9%	0.539	100%	77.8%	0.100	0.0%	40%
Serum Ab positive	38.9%	61.0%	0.100	28.6%	48.1%	0.321	66.7%	77.8%	0.100	100%	100%
Both Ab positive	33.3%	41.5%	0.386	28.6%	37.0%	0.734	66.7%	55.6%	0.100	0.0%	40%
Prior 1st-line immunotherapy; n (%)	100%	100%	-	100%	100%	-	100%	100%	-	100%	100%
1st-line therapy, n (%)											
MPPT	72.2%	97.6%	0.008	85.7%	93.3%	0.265	33.3%	100%	0.045	0	100%
IVIG	94.4%	46.3%	<.0001	92.9%	55.6%	0.031	100%	33.3%	0.182	100%	20%
Both	66.7%	43.9%	0.092	78.6%	51.9%	0.176	33.3%	33.3%	0.100	0	20%
RTX therapy											
Time from RTX therapy, days; median (IQR)	74.5 (410)	-	-	128.5 (405)	-	-	6 (1)	-	-	5 (1)	-
No. of RTX infusions, n; median (IQR)	5 (4)	-	-	5 (3)	-	-	3 (1)	-	-	3 (1)	-
Cumulative RTX dose, g; median (IQR)	500 (400)	-	-	500 (300)	-	-	300 (1)	-	-	300 (1)	-
1st to last infusion, days; median (IQR)	389 (864)	-	-	457.5 (863)	-	-	15 (1)	-	-	214 (1)	-
Averaged dose of prednisone, mg/day; median (IQR)	4.375 (7.67)	27.13 (21.67)	<.0001	5.563 (4.011)	28.89 (21.67)	<.0001	0	10.83 (19.52)	0.009	0	25.71 (20.057)
Relapses; n (%)											
After 1st-line therapy	33.3%	12.2%	0.074	42.9%	18.5%	0.140	33.3%	0.0%	0.250	0	0
After RTX therapy	0	-	-	0	-	-	0	-	-	0	-

NOTE: p values <0.05 are considered to be statistically significant, and are indicated in italic and bold italic AE autoimmune encephalitis, NMDAR N-methyl-D-aspartate receptor, LGI1 leucine-rich glioma-inactivated-1, CASPR2 contactin-associated protein-like-2, RTX rituximab, Ctrl control, CI confidence interval, IQR interquartile range, CSF cerebrospinal fluid, MRI magnetic resonance imaging, EEG electroencephalogram, cc cell count, Ab antibody, MPPT methylprednisolone pulse therapy, IVIG intravenous immunoglobulin.

Published online: 21 December 2022

Reference

1. Du Y, Zhao C, Liu J, Li C, Yan Q, Li L, Hao Y, Yao D, Si H, Zhao Y, Zhang W. Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies. *J Neuroinflammation*. 2022;19:259. <https://doi.org/10.1186/s12974-022-02622-8>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.